{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:07:47Z","timestamp":1785334067991,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum\/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (TP53, RB1) and amplifications in proto-oncogenes (MYC). We report a patient with SCBC who achieved an objective and prolonged response to lurbinectedin, which has been approved for metastatic small cell lung cancer, after developing disease progression on cisplatin\/etoposide and nivolumab\/ipilimumab. A genomic analysis of a metastatic biopsy prior to lurbinectedin initiation revealed a TP53 mutation and amplification of the cell cycle regulators E2F3 and MYCL. A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations\/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.<\/jats:p>","DOI":"10.3390\/curroncol31060254","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:42:06Z","timestamp":1718682126000},"page":"3342-3349","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7960-8614","authenticated-orcid":false,"given":"Mohammad Jad","family":"Moussa","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaanki","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel R.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar A.","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Sarah Cannon Research Institute, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12032-019-1321-x","article-title":"Small cell carcinoma of the bladder: The characteristics of molecular alterations, treatment, and follow-up","volume":"36","author":"Wang","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Moussa, M.J., Campbell, M.T., and Alhalabi, O. (2024). Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030519"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.euo.2023.09.004","article-title":"Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","article-title":"Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer","volume":"27","author":"Kamat","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: Lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1007\/s12325-021-01909-1","article-title":"Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion","volume":"38","author":"Das","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_7","unstructured":"Zepzelca (2024, June 07). Prices, Coupons, Copay & Patient Assistance\u2014Drugs.com. Available online: https:\/\/www.drugs.com\/price-guide\/zepzelca#."},{"key":"ref_8","unstructured":"(2024, May 02). 2369P Phase II Study of Nivolumab (Nivo) and Ipilimumab (Ipi) for Advanced Bladder Cancer with Variant Histologies (BCVH)\u2014Annals of Oncology. Available online: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(23)01854-9\/fulltext."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2024.42.4_suppl.667","article-title":"Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study","volume":"42","author":"Nizam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.2024.42.4_suppl.652","article-title":"Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study","volume":"42","author":"Jindal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"914342","DOI":"10.3389\/fonc.2022.914342","article-title":"Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma","volume":"12","author":"Gadducci","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","article-title":"Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study","volume":"28","author":"Subbiah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.04.002","article-title":"Lurbinectedin for metastatic small-cell bladder carcinoma","volume":"151","author":"Boudin","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113259","DOI":"10.1016\/j.ejca.2023.113259","article-title":"Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours","volume":"192","author":"Leary","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102441","DOI":"10.1016\/j.eucr.2023.102441","article-title":"A case of metastatic lung adenocarcinoma of the bladder in a patient with no documented history of lung cancer","volume":"49","author":"Azaiza","year":"2023","journal-title":"Urol. Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00345-022-04061-9","article-title":"Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer","volume":"40","author":"Carrasco","year":"2022","journal-title":"World J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1038\/sj.onc.1207749","article-title":"E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer","volume":"23","author":"Oeggerli","year":"2004","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2017.35.6_suppl.354","article-title":"Targeting ERBB2 mutations in urothelial carcinoma","volume":"35","author":"Audenet","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","unstructured":"My Cancer Genome (2024, April 28). ERBB2 S310F. Available online: https:\/\/www.mycancergenome.org\/content\/alteration\/erbb2-s310f\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.2024.42.4_suppl.601","article-title":"Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience","volume":"42","author":"Moussa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2024.42.4_suppl.164","article-title":"Lurbinectedin in prostatic small cell and neuroendocrine carcinoma","volume":"42","author":"Meyer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_30","unstructured":"(2023, December 11). Study Details. Lurbinectedin Monotherapy in Participants with Advanced or Metastatic Solid Tumors. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05126433."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"TPS4629","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4629","article-title":"A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER)","volume":"42","author":"Simon","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:58:06Z","timestamp":1760108286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["curroncol31060254"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31060254","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}